{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,30]],"date-time":"2026-05-30T02:53:25Z","timestamp":1780109605187,"version":"3.54.0"},"reference-count":112,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T00:00:00Z","timestamp":1665014400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Cardiovasc. Med."],"abstract":"<jats:p>Pulmonary arterial hypertension (PAH) is characterized by remodeling of the pulmonary arteries, and defined by elevated pulmonary arterial pressure, measured during right heart catheterization. There are three main challenges to the diagnostic and therapeutic process of patients with PAH. First, it is difficult to differentiate particular PAH etiology. Second, invasive diagnostic is required to precisely determine the severity of PAH, and thus to qualify patients for an appropriate treatment. Third, the results of treatment of PAH are unpredictable and remain unsatisfactory. MicroRNAs (miRNAs) are small non-coding RNAs that regulate post transcriptional gene-expression. Their role as a prognostic, and diagnostic biomarkers in many different diseases have been studied in recent years. MiRNAs are promising novel biomarkers in PAH due to their activity in various molecular pathways and processes underlying PAH. Lack of biomarkers to differentiate between particular PAH etiology and evaluate the severity of PAH, as well as paucity of therapeutic targets in PAH open a new field for the possibility to use miRNAs in these applications. In our article, we discuss the potential of miRNAs use as diagnostic tools, prognostic biomarkers and therapeutic targets in PAH.<\/jats:p>","DOI":"10.3389\/fcvm.2022.980718","type":"journal-article","created":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:21:15Z","timestamp":1665055275000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":8,"title":["Biomarker-based approach to determine etiology and severity of pulmonary hypertension: Focus on microRNA"],"prefix":"10.3389","volume":"9","author":[{"given":"Sylwester","family":"Rogula","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bartosz","family":"Pomirski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Norbert","family":"Czy\u017cak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ceren","family":"Eyileten","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marek","family":"Postu\u0142a","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u0141ukasz","family":"Szarpak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Krzysztof J.","family":"Filipiak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Kurzyna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mi\u0142osz","family":"Jaguszewski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomasz","family":"Mazurek","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marcin","family":"Grabowski","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aleksandra","family":"G\u0105secka","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2022,10,6]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1164\/rccm.202012-4317SO","article-title":"Pulmonary arterial hypertension: diagnosis, treatment, and novel advances.","volume":"203","author":"Maron","year":"2021","journal-title":"Am J Respir Crit Care Med."},{"key":"B2","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1183\/09031936.00092306","article-title":"An epidemiological study of pulmonary arterial hypertension.","volume":"30","author":"Peacock","year":"2007","journal-title":"Eur Respir J."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1149","DOI":"10.1016\/j.jacbts.2020.07.008","article-title":"Micro-RNA analysis in pulmonary arterial hypertension: current knowledge and challenges.","volume":"5","author":"Santos-Ferreira","year":"2020","journal-title":"JACC Basic Transl Sci."},{"key":"B4","doi-asserted-by":"publisher","first-page":"D34","DOI":"10.1016\/j.jacc.2013.10.029","article-title":"Updated clinical classification of pulmonary hypertension.","volume":"62","author":"Simonneau","year":"2013","journal-title":"J Am Coll Cardiol."},{"key":"B5","doi-asserted-by":"publisher","first-page":"1023","DOI":"10.1164\/rccm.200510-1668OC","article-title":"Pulmonary arterial hypertension in France: results from a national registry.","volume":"173","author":"Humbert","year":"2006","journal-title":"Am J Respir Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1136\/hrt.2006.098848","article-title":"Pulmonary arterial hypertension in adults born with a heart septal defect: the Euro Heart Survey on adult congenital heart disease.","volume":"93","author":"Engelfriet","year":"2007","journal-title":"Heart."},{"key":"B7","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1093\/eurheartj\/ehv317","article-title":"2015 ESC\/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the joint task force for the diagnosis and treatment of pulmonary hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS): endor.","volume":"37","author":"Gali\u00e8","year":"2016","journal-title":"Eur Heart J."},{"key":"B8","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1164\/rccm.200802-235OC","article-title":"Growth differentiation factor-15 in idiopathic pulmonary arterial hypertension.","volume":"178","author":"Nickel","year":"2008","journal-title":"Am J Respir Crit Care Med."},{"key":"B9","doi-asserted-by":"publisher","DOI":"10.1186\/s12931-016-0396-6","article-title":"Novel biomarkers for pulmonary arterial hypertension.","volume":"17","author":"Anwar","year":"2016","journal-title":"Respir Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"661","DOI":"10.1177\/0300060515589394","article-title":"Prognostic value of neutrophil-to-lymphocyte ratio in pulmonary arterial hypertension.","volume":"43","author":"\u00d6zpelit","year":"2015","journal-title":"J Int Med Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"270","DOI":"10.4081\/reumatismo.2014.774","article-title":"Elevated serum levels of macrophage migration inhibitory factor and stem cell growth factor $\u03b2$ in patients with idiopathic and systemic sclerosis associated pulmonary arterial hypertension.","volume":"66","author":"Stefanantoni","year":"2014","journal-title":"Reumatismo."},{"key":"B12","doi-asserted-by":"publisher","first-page":"869","DOI":"10.1378\/chest.11-1267","article-title":"Independent association of urinary F2-isoprostanes with survival in pulmonary arterial hypertension.","volume":"142","author":"Cracowski","year":"2012","journal-title":"Chest."},{"key":"B13","doi-asserted-by":"publisher","DOI":"10.3390\/jcm11020383","article-title":"Circulating blood-based biomarkers in pulmonary hypertension.","volume":"11","author":"Banaszkiewicz","year":"2022","journal-title":"J Clin Med."},{"key":"B14","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2018.00402","article-title":"Overview of MicroRNA biogenesis, mechanisms of actions, and circulation.","volume":"9","author":"O\u2019Brien","year":"2018","journal-title":"Front Endocrinol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1007\/978-1-4939-6524-3_1","article-title":"MiRNA biogenesis and regulation of diseases: an overview.","volume":"1509","author":"Vishnoi","year":"2017","journal-title":"Methods Mol. Biol."},{"key":"B16","doi-asserted-by":"publisher","DOI":"10.1186\/s12933-021-01245-2","article-title":"MicroRNAs and long non-coding RNAs in the pathophysiological processes of diabetic cardiomyopathy: emerging biomarkers and potential therapeutics.","volume":"20","author":"Jakubik","year":"2021","journal-title":"Cardiovasc Diabetol."},{"key":"B17","doi-asserted-by":"publisher","first-page":"601","DOI":"10.1016\/j.ccl.2020.07.005","article-title":"MicroRNAs and long noncoding RNAs in coronary artery disease: new and potential therapeutic targets.","volume":"38","author":"Zareba","year":"2020","journal-title":"Cardiol Clin."},{"key":"B18","doi-asserted-by":"publisher","DOI":"10.3390\/cells7120249","article-title":"MicroRNAs as diagnostic and prognostic biomarkers in ischemic stroke\u2014a comprehensive review and bioinformatic analysis.","volume":"7","author":"Eyileten","year":"2018","journal-title":"Cells."},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10112371","article-title":"Mir-126 is an independent predictor of long-term all-cause mortality in patients with type 2 diabetes mellitus.","volume":"10","author":"Pordzik","year":"2021","journal-title":"J Clin Med."},{"key":"B20","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1165\/rcmb.2014-0166TR","article-title":"MicroRNAs in pulmonary arterial hypertension.","volume":"52","author":"Zhou","year":"2015","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"115","DOI":"10.1161\/CIRCRESAHA.115.301146","article-title":"Pulmonary arterial hypertension: the clinical syndrome.","volume":"115","author":"Lai","year":"2014","journal-title":"Circ Res."},{"key":"B22","doi-asserted-by":"publisher","DOI":"10.1183\/13993003.01887-2018","article-title":"Pathology and pathobiology of pulmonary hypertension: state of the art and research perspectives.","volume":"53","author":"Humbert","year":"2019","journal-title":"Eur Respir J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"159","DOI":"10.1161\/01.CIR.0000102381.57477.50","article-title":"Current perspective.","volume":"109","author":"Budhiraja","year":"2004","journal-title":"Circulation."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.3390\/diseases6020038","article-title":"Pulmonary arterial hypertension: pathophysiology and treatment.","volume":"6","author":"Lan","year":"2018","journal-title":"Diseases."},{"key":"B25","doi-asserted-by":"publisher","first-page":"533","DOI":"10.1161\/01.CIR.18.4.533","article-title":"The pathology of hypertensive pulmonary vascular disease: a description of six grades of structural changes in the pulmonary arteries with special reference to congenital cardiac septal defects.","volume":"18","author":"Heath","year":"1958","journal-title":"Circulation."},{"key":"B26","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1093\/ejechocard\/jep152","article-title":"Right ventricle in pulmonary arterial hypertension: haemodynamics, structural changes, imaging, and proposal of a study protocol aimed to assess remodelling and treatment effects.","volume":"11","author":"Badano","year":"2010","journal-title":"Eur J Echocardiogr."},{"key":"B27","doi-asserted-by":"publisher","first-page":"716","DOI":"10.1161\/ATVBAHA.109.202028","article-title":"Dynamic changes in lung microRNA profiles during the development of pulmonary hypertension due to chronic hypoxia and monocrotaline.","volume":"30","author":"Caruso","year":"2010","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"185","DOI":"10.1086\/675981","article-title":"MicroRNAs in right ventricular (dys) function (2013 Grover Conference series).","volume":"4","author":"Thum","year":"2014","journal-title":"Pulm Circ."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1239","DOI":"10.1165\/rcmb.2010-0412OC","article-title":"Molecular signature of a right heart failure program in chronic severe pulmonary hypertension.","volume":"45","author":"Drake","year":"2011","journal-title":"Am J Respir Cell Mol Biol."},{"key":"B30","doi-asserted-by":"publisher","DOI":"10.1177\/2045894019840646","article-title":"Distinct plasma gradients of microRNA-204 in the pulmonary circulation of patients suffering from WHO Groups I and II pulmonary hypertension.","volume":"9","author":"Estephan","year":"2019","journal-title":"Pulm Circ."},{"key":"B31","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1084\/jem.20101812","article-title":"Role for miR-204 in human pulmonary arterial hypertension.","volume":"208","author":"Courboulin","year":"2011","journal-title":"J Exp Med."},{"key":"B32","doi-asserted-by":"publisher","first-page":"2601","DOI":"10.1161\/CIRCULATIONAHA.112.114173","article-title":"Exosomes mediate the cytoprotective action of mesenchymal stromal cells on hypoxia-induced pulmonary hypertension.","volume":"126","author":"Lee","year":"2012","journal-title":"Circulation."},{"key":"B33","doi-asserted-by":"publisher","first-page":"764","DOI":"10.1016\/j.healun.2012.03.010","article-title":"Plexiform vasculopathy of severe pulmonary arterial hypertension and microRNA expression.","volume":"31","author":"Bockmeyer","year":"2012","journal-title":"J Hear Lung Transplant."},{"key":"B34","doi-asserted-by":"publisher","first-page":"1513","DOI":"10.1161\/ATVBAHA.117.309156","article-title":"Implication of inflammation and epigenetic readers in coronary artery remodeling in patients with pulmonary arterial hypertension.","volume":"37","author":"Meloche","year":"2017","journal-title":"Arterioscler Thromb Vasc Biol."},{"key":"B35","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1161\/CIRCRESAHA.114.301633","article-title":"MicroRNA-124 controls the proliferative, migratory, and inflammatory phenotype of pulmonary vascular fibroblasts.","volume":"114","author":"Wang","year":"2014","journal-title":"Circ Res."},{"key":"B36","doi-asserted-by":"publisher","first-page":"672","DOI":"10.1111\/j.1365-2141.2008.07077.x","article-title":"Detection of elevated levels of tumour-associated microRNAs in serum of patients with diffuse large B-cell lymphoma.","volume":"141","author":"Lawrie","year":"2008","journal-title":"Br J Haematol."},{"key":"B37","doi-asserted-by":"publisher","first-page":"1733","DOI":"10.1373\/clinchem.2010.147405","article-title":"The microRNA spectrum in 12 body fluids.","volume":"56","author":"Weber","year":"2010","journal-title":"Clin Chem."},{"key":"B38","doi-asserted-by":"publisher","first-page":"483","DOI":"10.1161\/CIRCRESAHA.111.247452","article-title":"Circulating microRNAs: novel biomarkers and extracellular communicators in cardiovascular disease?","volume":"110","author":"Creemers","year":"2012","journal-title":"Circ Res."},{"key":"B39","doi-asserted-by":"publisher","DOI":"10.3389\/fphys.2017.01028","article-title":"Extracellular vesicle microRNA transfer in lung diseases.","volume":"8","author":"Chen","year":"2017","journal-title":"Front Physiol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"10513","DOI":"10.1073\/pnas.0804549105","article-title":"Circulating microRNAs as stable blood-based markers for cancer detection.","volume":"105","author":"Mitchell","year":"2008","journal-title":"Proc Natl Acad Sci USA."},{"key":"B41","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1038\/cr.2008.282","article-title":"Characterization of microRNAs in serum: a novel class of biomarkers for diagnosis of cancer and other diseases.","volume":"18","author":"Chen","year":"2008","journal-title":"Cell Res."},{"key":"B42","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1177\/1535370215579018","article-title":"Featured article: microRNA-125a in pulmonary hypertension: regulator of a proliferative phenotype of endothelial cells.","volume":"240","author":"Huber","year":"2015","journal-title":"Exp Biol Med."},{"key":"B43","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1038\/79226","article-title":"Heterozygous germline mutations in BMPR2, encoding a TGF-$\u03b2$ receptor, cause familial primary pulmonary hypertension.","volume":"26","author":"Lane","year":"2000","journal-title":"Nat Genet."},{"key":"B44","doi-asserted-by":"publisher","first-page":"S32","DOI":"10.1016\/j.jacc.2009.04.015","article-title":"Genetics and genomics of pulmonary arterial hypertension.","volume":"54","author":"Machado","year":"2009","journal-title":"J Am Coll Cardiol."},{"key":"B45","doi-asserted-by":"publisher","first-page":"1204","DOI":"10.1056\/NEJMoa2024277","article-title":"Sotatercept for the treatment of pulmonary arterial hypertension.","volume":"384","author":"Humbert","year":"2021","journal-title":"N Engl J Med."},{"key":"B46","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.j5492","article-title":"Pulmonary arterial hypertension: pathogenesis and clinical management.","volume":"360","author":"Thenappan","year":"2018","journal-title":"BMJ."},{"key":"B47","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1164\/rccm.201205-0839OC","article-title":"Reduced microRNA-150 is associated with poor survival in pulmonary arterial hypertension.","volume":"187","author":"Rhodes","year":"2013","journal-title":"Am J Respir Crit Care Med."},{"key":"B48","doi-asserted-by":"publisher","first-page":"249","DOI":"10.1038\/ncb2441","article-title":"Atheroprotective communication between endothelial cells and smooth muscle cells through miRNAs.","volume":"14","author":"Hergenreider","year":"2012","journal-title":"Nat Cell Biol."},{"key":"B49","doi-asserted-by":"publisher","first-page":"H273","DOI":"10.1152\/ajpheart.00741.2017","article-title":"Specific circulating microRNAs display dose-dependent responses to variable intensity and duration of endurance exercise.","volume":"315","author":"Ramos","year":"2018","journal-title":"Am J Physiol Circ Physiol."},{"key":"B50","doi-asserted-by":"publisher","first-page":"786","DOI":"10.1161\/CIRCULATIONAHA.113.006167","article-title":"Role for DNA damage signaling in pulmonary arterial hypertension.","volume":"129","author":"Meloche","year":"2014","journal-title":"Circulation."},{"key":"B51","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1097\/PCC.0000000000002207","article-title":"Trans-right\u2013ventricle and transpulmonary MicroRNA gradients in human pulmonary arterial hypertension.","volume":"21","author":"Chouvarine","year":"2020","journal-title":"Pediatr Crit Care Med."},{"key":"B52","doi-asserted-by":"publisher","first-page":"687","DOI":"10.1515\/cclm-2016-0576","article-title":"microRNAs in cardiovascular disease\u2013clinical application.","volume":"55","author":"Schulte","year":"2017","journal-title":"Clin Chem Lab Med."},{"key":"B53","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000078","article-title":"Therapeutic cardiac-targeted delivery of miR-1 reverses pressure overload\u2013induced cardiac hypertrophy and attenuates pathological remodeling.","volume":"2","author":"Karakikes","year":"2013","journal-title":"J Am Heart Assoc."},{"key":"B54","doi-asserted-by":"publisher","first-page":"840","DOI":"10.1161\/CIRCULATIONAHA.112.094524","article-title":"MicroRNA-101 inhibited postinfarct cardiac fibrosis and improved left ventricular compliance via the FBJ osteosarcoma oncogene\/transforming growth factor-$\u03b2$1 pathway.","volume":"126","author":"Pan","year":"2012","journal-title":"Circulation."},{"key":"B55","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1159\/000347081","article-title":"Overexpression of MicroRNA-1 improves the efficacy of mesenchymal stem cell transplantation after myocardial infarction.","volume":"125","author":"Huang","year":"2013","journal-title":"Cardiology."},{"key":"B56","doi-asserted-by":"publisher","first-page":"221","DOI":"10.1016\/j.jash.2014.12.011","article-title":"MicroRNAs in pulmonary arterial hypertension: pathogenesis, diagnosis and treatment.","volume":"9","author":"Bienertova-Vasku","year":"2015","journal-title":"J Am Soc Hypertens."},{"key":"B57","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1517\/14728222.2013.765863","article-title":"MicroRNAs: promising therapeutic targets for the treatment of pulmonary arterial hypertension.","volume":"17","author":"Yuan","year":"2013","journal-title":"Expert Opin Ther Targets."},{"key":"B58","doi-asserted-by":"publisher","first-page":"2781","DOI":"10.1161\/01.CIR.102.22.2781","article-title":"Primary pulmonary hypertension: a vascular biology and translational research \u201cWork in progress.\u201d.","volume":"102","author":"Archer","year":"2000","journal-title":"Circulation."},{"key":"B59","doi-asserted-by":"publisher","first-page":"409","DOI":"10.1164\/rccm.201106-1093OC","article-title":"Inhibition of microRNA-17 improves lung and heart function in experimental pulmonary hypertension.","volume":"185","author":"Pullamsetti","year":"2012","journal-title":"Am J Respir Crit Care Med."},{"key":"B60","doi-asserted-by":"publisher","first-page":"481","DOI":"10.1378\/chest.14-2169","article-title":"Discordant regulation of microRNA between multiple experimental models and human pulmonary hypertension.","volume":"148","author":"Schlosser","year":"2015","journal-title":"Chest."},{"key":"B61","doi-asserted-by":"publisher","first-page":"1937","DOI":"10.1093\/cvr\/cvaa050","article-title":"Pathobiology of pulmonary artery hypertension: role of long non-coding RNAs.","volume":"116","author":"Zahid","year":"2020","journal-title":"Cardiovasc Res."},{"key":"B62","doi-asserted-by":"publisher","first-page":"1664","DOI":"10.1007\/s12035-020-02206-8","article-title":"Long non-coding RNAs as promising therapeutic approach in ischemic stroke: a comprehensive review.","volume":"58","author":"Wolska","year":"2021","journal-title":"Mol Neurobiol."},{"key":"B63","doi-asserted-by":"publisher","DOI":"10.3390\/jcm10010009","article-title":"The importance of non-coding RNAs in neurodegenerative processes of diabetes-related molecular pathways.","volume":"10","author":"Jarosz-Popek","year":"2020","journal-title":"J Clin Med."},{"key":"B64","doi-asserted-by":"publisher","DOI":"10.3390\/cells10081892","article-title":"Role of long non-coding RNAs in pulmonary arterial hypertension.","volume":"10","author":"Han","year":"2021","journal-title":"Cells."},{"key":"B65","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/nature21374","article-title":"An atlas of human long non-coding RNAs with accurate 5\u2032 ends.","volume":"543","author":"Hon","year":"2017","journal-title":"Nature."},{"key":"B66","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-3-319-22671-2_12","article-title":"microRNA and pulmonary hypertension.","volume":"888","author":"Boucherat","year":"2015","journal-title":"Adv Exp Med Biol."},{"key":"B67","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.113.000792","article-title":"Circulating microRNAs: understanding the limits for quantitative measurement by real-time PCR.","volume":"3","author":"Hardikar","year":"2014","journal-title":"J Am Heart Assoc."},{"key":"B68","doi-asserted-by":"publisher","DOI":"10.1007\/s11883-015-0548-z","article-title":"MicroRNA biomarkers for coronary artery disease?","volume":"17","author":"Kaudewitz","year":"2015","journal-title":"Curr Atheroscler Rep."},{"key":"B69","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0153691","article-title":"Discordant expression of circulating microRNA from cellular and extracellular sources.","volume":"11","author":"Shah","year":"2016","journal-title":"PLoS One."},{"key":"B70","doi-asserted-by":"publisher","DOI":"10.1177\/0300060520920430","article-title":"MicroRNA-17 as a potential diagnostic biomarker in pulmonary arterial hypertension.","volume":"48","author":"Li","year":"2020","journal-title":"J Int Med Res."},{"key":"B71","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1016\/j.healun.2014.12.005","article-title":"Circulating biomarkers in pulmonary arterial hypertension: update and future direction.","volume":"34","author":"Pezzuto","year":"2015","journal-title":"J Hear Lung Transplant."},{"key":"B72","doi-asserted-by":"publisher","DOI":"10.1016\/j.ebiom.2021.103444","article-title":"A diagnostic miRNA signature for pulmonary arterial hypertension using a consensus machine learning approach.","volume":"69","author":"Errington","year":"2021","journal-title":"EBioMedicine."},{"key":"B73","doi-asserted-by":"publisher","first-page":"607","DOI":"10.1016\/j.ebiom.2019.08.027","article-title":"Looking beyond the hype: applied AI and machine learning in translational medicine.","volume":"47","author":"Toh","year":"2019","journal-title":"EBioMedicine."},{"key":"B74","doi-asserted-by":"publisher","DOI":"10.1155\/2015\/198363","article-title":"A review of feature selection and feature extraction methods applied on microarray data.","volume":"2015","author":"Hira","year":"2015","journal-title":"Adv Bioinformatics."},{"key":"B75","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1016\/j.jcrc.2017.07.014","article-title":"Mechanical ventilation weaning protocol improves medical adherence and results.","volume":"41","author":"Borges","year":"2017","journal-title":"J Crit Care."},{"key":"B76","doi-asserted-by":"publisher","first-page":"444","DOI":"10.4161\/cc.6.4.3807","article-title":"Gene silencing by small regulatory RNAs in mammalian cells.","volume":"6","author":"Scherr","year":"2007","journal-title":"Cell Cycle."},{"key":"B77","doi-asserted-by":"publisher","DOI":"10.3390\/ijms21093253","article-title":"MicroRNA nanotherapeutics for lung targeting. Insights into pulmonary hypertension.","volume":"21","author":"Carregal-Romero","year":"2020","journal-title":"Int J Mol Sci."},{"key":"B78","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1093\/nar\/gkx1239","article-title":"Chemistry, mechanism and clinical status of antisense oligonucleotides and duplex RNAs.","volume":"46","author":"Shen","year":"2018","journal-title":"Nucleic Acids Res."},{"key":"B79","doi-asserted-by":"publisher","first-page":"91","DOI":"10.1016\/j.pharmthera.2018.11.011","article-title":"RNA therapy: are we using the right molecules?","volume":"196","author":"Yu","year":"2019","journal-title":"Pharmacol Ther."},{"key":"B80","doi-asserted-by":"publisher","DOI":"10.7150\/thno.22912","article-title":"Systematic assessment of strategies for lung-targeted delivery of microRNA mimics.","volume":"8","author":"Schlosser","year":"2018","journal-title":"Theranostics."},{"key":"B81","doi-asserted-by":"publisher","first-page":"2873","DOI":"10.1093\/nar\/gkw040","article-title":"Identification of factors involved in target RNA-directed microRNA degradation.","volume":"44","author":"Haas","year":"2016","journal-title":"Nucleic Acids Res."},{"key":"B82","doi-asserted-by":"publisher","first-page":"1111","DOI":"10.1038\/gt.2011.100","article-title":"Chemical modification and design of anti-miRNA oligonucleotides.","volume":"18","author":"Lennox","year":"2011","journal-title":"Gene Ther."},{"key":"B83","doi-asserted-by":"publisher","first-page":"106","DOI":"10.1016\/j.bcp.2018.11.013","article-title":"Comparison of different chemically modified inhibitors of miR-199b in vivo.","volume":"159","author":"Duygu","year":"2019","journal-title":"Biochem Pharmacol."},{"key":"B84","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1016\/j.intimp.2018.12.043","article-title":"Extracellular vesicles containing miR-146a attenuate experimental colitis by targeting TRAF6 and IRAK1.","volume":"68","author":"Wu","year":"2019","journal-title":"Int Immunopharmacol."},{"key":"B85","doi-asserted-by":"publisher","first-page":"1088","DOI":"10.4161\/rna.21165","article-title":"PEI-complexed LNA antiseeds as miRNA inhibitors.","volume":"9","author":"Thomas","year":"2012","journal-title":"RNA Biol."},{"key":"B86","doi-asserted-by":"publisher","DOI":"10.2147\/IJN.S182384","article-title":"Exosome-mediated delivery of functionally active miRNA-142-3p inhibitor reduces tumorigenicity of breast cancer in vitro and in vivo.","volume":"13","author":"Naseri","year":"2018","journal-title":"Int J Nanomedicine."},{"key":"B87","doi-asserted-by":"publisher","DOI":"10.3390\/ijms17060765","article-title":"MicroRNA-24 attenuates neointimal hyperplasia in the diabetic rat carotid artery injury model by inhibiting Wnt4 signaling pathway.","volume":"17","author":"Yang","year":"2016","journal-title":"Int J Mol Sci."},{"key":"B88","doi-asserted-by":"publisher","first-page":"2851","DOI":"10.1089\/scd.2014.0146","article-title":"Mesenchymal stem cells deliver exogenous miRNAs to neural cells and induce their differentiation and glutamate transporter expression.","volume":"23","author":"Lee","year":"2014","journal-title":"Stem Cells Dev."},{"key":"B89","doi-asserted-by":"publisher","first-page":"534","DOI":"10.1016\/j.coph.2010.06.007","article-title":"Viral vector-mediated RNA interference.","volume":"10","author":"Couto","year":"2010","journal-title":"Curr Opin Pharmacol."},{"key":"B90","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.jconrel.2016.09.016","article-title":"Good things come in small packages: overcoming challenges to harness extracellular vesicles for therapeutic delivery.","volume":"241","author":"Ingato","year":"2016","journal-title":"J Control Release."},{"key":"B91","doi-asserted-by":"publisher","first-page":"864","DOI":"10.1038\/s41929-019-0333-4","article-title":"Cancer-derived exosomes loaded with ultrathin palladium nanosheets for targeted bioorthogonal catalysis.","volume":"2","author":"Sancho-Albero","year":"2019","journal-title":"Nat Catal."},{"key":"B92","doi-asserted-by":"publisher","first-page":"1517","DOI":"10.1016\/j.nano.2014.03.014","article-title":"Exosome-mediated delivery of functionally active miRNA-155 inhibitor to macrophages.","volume":"10","author":"Momen-Heravi","year":"2014","journal-title":"Nanomedicine."},{"key":"B93","doi-asserted-by":"publisher","first-page":"1209","DOI":"10.1039\/C8TB02946F","article-title":"Non-viral nanocarriers for intracellular delivery of microRNA therapeutics.","volume":"7","author":"Bai","year":"2019","journal-title":"J Mater Chem B."},{"key":"B94","doi-asserted-by":"publisher","DOI":"10.1002\/adhm.201801318","article-title":"Biodegradable polymers as a noncoding miRNA nanocarrier for multiple targeting therapy of human hepatocellular carcinoma.","volume":"8","author":"Yang","year":"2019","journal-title":"Adv Healthc Mater."},{"key":"B95","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejps.2017.01.031","article-title":"The vector-related influences of autophagic microRNA delivery by Lipofectamine 2000 and polyethylenimine 25K on mouse embryonic fibroblast cells.","volume":"101","author":"Lin","year":"2017","journal-title":"Eur J Pharm Sci."},{"key":"B96","doi-asserted-by":"publisher","first-page":"158","DOI":"10.1161\/CIRCRESAHA.109.197517","article-title":"MicroRNA-145, a novel smooth muscle cell phenotypic marker and modulator, controls vascular neointimal lesion formation.","volume":"105","author":"Cheng","year":"2009","journal-title":"Circ Res."},{"key":"B97","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1016\/j.bbrc.2017.11.185","article-title":"Down-regulation of lncRNA MEG3 promotes hypoxia-induced human pulmonary artery smooth muscle cell proliferation and migration via repressing PTEN by sponging miR-21.","volume":"495","author":"Zhu","year":"2018","journal-title":"Biochem Biophys Res Commun."},{"key":"B98","doi-asserted-by":"publisher","first-page":"1520","DOI":"10.1161\/CIRCULATIONAHA.111.060269","article-title":"MicroRNA-21 integrates pathogenic signaling to control pulmonary hypertension: results of a network bioinformatics approach.","volume":"125","author":"Parikh","year":"2012","journal-title":"Circulation."},{"key":"B99","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0005436","article-title":"Tissue and process specific microRNA\u2013mRNA co-expression in mammalian development and malignancy.","volume":"4","author":"Liu","year":"2009","journal-title":"PLoS One."},{"key":"B100","doi-asserted-by":"publisher","first-page":"53","DOI":"10.1093\/cvr\/cvx187","article-title":"MicroRNA-424 (322) as a new marker of disease progression in pulmonary arterial hypertension and its role in right ventricular hypertrophy by targeting SMURF1.","volume":"114","author":"Baptista","year":"2018","journal-title":"Cardiovasc Res."},{"key":"B101","doi-asserted-by":"publisher","first-page":"1400","DOI":"10.1164\/rccm.201106-1130OC","article-title":"Altered MicroRNA processing in heritable pulmonary arterial hypertension: an important role for Smad-8.","volume":"184","author":"Drake","year":"2011","journal-title":"Am J Respir Crit Care Med."},{"key":"B102","doi-asserted-by":"publisher","first-page":"414","DOI":"10.1161\/HYPERTENSIONAHA.114.04600","article-title":"miR-29a-3p attenuates hypoxic pulmonary hypertension by inhibiting pulmonary adventitial fibroblast activation.","volume":"65","author":"Luo","year":"2015","journal-title":"Hypertension."},{"key":"B103","doi-asserted-by":"publisher","first-page":"342","DOI":"10.1016\/j.bbrc.2016.03.116","article-title":"MiR-140-5p regulates hypoxia-mediated human pulmonary artery smooth muscle cell proliferation, apoptosis and differentiation by targeting Dnmt1 and promoting SOD2 expression.","volume":"473","author":"Zhang","year":"2016","journal-title":"Biochem Biophys Res Commun."},{"key":"B104","doi-asserted-by":"publisher","first-page":"L682","DOI":"10.1152\/ajplung.00344.2011","article-title":"miR-210 has an antiapoptotic effect in pulmonary artery smooth muscle cells during hypoxia.","volume":"303","author":"Gou","year":"2012","journal-title":"Am J Physiol Cell Mol Physiol."},{"key":"B105","doi-asserted-by":"publisher","first-page":"1445","DOI":"10.1164\/rccm.201910-2041OC","article-title":"Long noncoding RNA TYKRIL plays a role in pulmonary hypertension via the p53-mediated regulation of PDGFR.","volume":"202","author":"Zehendner","year":"2020","journal-title":"Am J Respir Crit Care Med."},{"key":"B106","doi-asserted-by":"publisher","first-page":"357","DOI":"10.1002\/path.5195","article-title":"Long non-coding RNAs influence the transcriptome in pulmonary arterial hypertension: the role of PAXIP1-AS1.","volume":"247","author":"Jandl","year":"2019","journal-title":"J Pathol."},{"key":"B107","doi-asserted-by":"publisher","first-page":"647","DOI":"10.1093\/cvr\/cvy250","article-title":"Long noncoding RNA Hoxaas3 contributes to hypoxia-induced pulmonary artery smooth muscle cell proliferation.","volume":"115","author":"Zhang","year":"2019","journal-title":"Cardiovasc Res."},{"key":"B108","doi-asserted-by":"publisher","first-page":"871","DOI":"10.3892\/ijmm.2019.4256","article-title":"Long non-coding RNA MALAT1 sponges miR-124-3p. 1\/KLF5 to promote pulmonary vascular remodeling and cell cycle progression of pulmonary artery hypertension.","volume":"44","author":"Wang","year":"2019","journal-title":"Int J Mol Med."},{"key":"B109","doi-asserted-by":"publisher","DOI":"10.12659\/MSM.923123","article-title":"Long-chain non-coding RNA metastasis-related lung adenocarcinoma transcript 1 (MALAT1) promotes the proliferation and migration of human pulmonary artery smooth muscle cells (hPASMCs) by regulating the microRNA-503 (miR-503)\/toll-like receptor 4 (TLR4) si.","volume":"26","author":"He","year":"2020","journal-title":"Med Sci Monit Int Med J Exp Clin Res."},{"key":"B110","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1007\/s00424-018-2219-8","article-title":"Long noncoding RNA UCA1 promotes the proliferation of hypoxic human pulmonary artery smooth muscle cells.","volume":"471","author":"Zhu","year":"2019","journal-title":"Pfl\u00fcgers Arch J Physiol."},{"key":"B111","doi-asserted-by":"publisher","first-page":"239","DOI":"10.1007\/s11010-020-03877-6","article-title":"LincRNA-Cox2 promotes pulmonary arterial hypertension by regulating the let-7a-mediated STAT3 signaling pathway.","volume":"475","author":"Cheng","year":"2020","journal-title":"Mol Cell Biochem."},{"key":"B112","doi-asserted-by":"publisher","DOI":"10.1016\/j.vph.2021.106886","article-title":"The lncRNA PAHRF functions as a competing endogenous RNA to regulate MST1 expression by sponging miR-23a-3p in pulmonary arterial hypertension.","volume":"139","author":"Liu","year":"2021","journal-title":"Vascul Pharmacol."}],"container-title":["Frontiers in Cardiovascular Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.980718\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,10,6]],"date-time":"2022-10-06T11:21:19Z","timestamp":1665055279000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fcvm.2022.980718\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,10,6]]},"references-count":112,"alternative-id":["10.3389\/fcvm.2022.980718"],"URL":"https:\/\/doi.org\/10.3389\/fcvm.2022.980718","relation":{},"ISSN":["2297-055X"],"issn-type":[{"value":"2297-055X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,10,6]]},"article-number":"980718"}}